Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Gulf Chronic Care, Inc. was established specifically to address the diabetic epide...
Gulf Chronic Care, Inc. was established specifi...
We are a patient-centric, clinical-stage biopharmaceutical company dedicated to br...
We are a patient-centric, clinical-stage biopha...
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with ...
Co-Diagnostics, Inc., a Utah corporation, is a ...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
Join the National Investor Network and get the latest information with your interests in mind.